Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, "The positive Phase 3 MAESTRO-NASH results reported in Q4 2022 have allowed us to advance our regulatory filing preparations, accelerate our prelaunch market development programs, and strengthen our financial position with funding to support the company’s operations through the potential accelerated approval of resmetirom in the U.S. The results have also reinforced our conviction in the value of resmetirom. The Institute for Clinical and Economic Review, a non-profit organization that conducts pharmacoeconomic assessments of new therapies, recently published a draft Evidence Report indicating that resmetirom has the potential to be a cost-effective treatment for NASH patients with significant fibrosis."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
- Looking for Powerful Healthcare Stocks? These 5 Made Enormous Profit in 2022
- Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler